Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Patients with follicular lymphoma (FL) who experience progression of disease within 24 months (POD24) of receiving first-line therapy had a significantly poorer prognosis than that without early progression. Due to the established prognostic relevance of positron emission tomography/computed tomography (PET/CT) parameters in FL and their clinical accessibility, we aimed to investigate the predictive role of PET/CT metabolism and dissemination parameters in POD24 for FL.

Methods: The POD24 status of 155 patients who underwent PET/CT examinations at initial diagnosis was evaluated. Various baseline characteristics were collected, along with PET/CT-derived parameters, including the maximum tumor dissemination (Dmax), maximum standardized uptake (SUVmax) value, total metabolic tumor volume (TMTV), and total lesion glycolysis (TLG). A Cox proportional regression analysis was used to identify potential risk predictors of POD24. Receiver operating characteristic (ROC) curves were used to define the optimal cut-off values.

Results: In our cohort, POD24 was observed in 21 (13.5%) FL patients. The univariate and multivariate Cox regression analyses revealed that elevated lactate dehydrogenase (LDH) was a significant predictor of POD24. Additionally, survival analyses based on the cut-off values showed that the risk of POD24 was significantly increased in patients with a Dmax >64.24 cm, SUVmax >11.23, TMTV >144.16 cm, and TLG >586.79 g. Further, a Dmax >64.24 cm, a TMTV >144.16 cm, and elevated LDH were selected for inclusion in a risk model [concordance index (C-index) =0.82], and the patients were divided into three risk groups, in which the rates of POD24 were 1.69%, 10.42%, and 35.29%, respectively (P<0.001). Our model exhibited excellent performance in terms of both the C-index and ROC curve analysis, surpassing the performance of models commonly used in the field.

Conclusions: PET/CT parameters have prognostic value for POD24 in FL. The risk model, which combined PET/CT parameters with clinical indicators, could improve risk stratification and help guide therapeutic decisions.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11948388PMC
http://dx.doi.org/10.21037/qims-24-1504DOI Listing

Publication Analysis

Top Keywords

pod24
9
pet/ct parameters
8
parameters clinical
8
progression disease
8
disease months
8
months pod24
8
follicular lymphoma
8
dmax >6424
8
tmtv >14416
8
risk
5

Similar Publications

: Classical follicular lymphoma (FL) is a heterogeneous malignancy. Early progression within 24 months (POD24) is linked to poor outcomes. However, precise risk stratification remains unclear.

View Article and Find Full Text PDF

Prognostic factors and effect modifiers in patients with relapsed or refractory follicular lymphoma who failed at least two lines of therapy: a systematic literature and expert clinical review.

Ann Hematol

September 2025

Department of Hematology and Stem Cell Transplantation, West German Cancer Center, and German Cancer Consortium (DKTK partner site Essen), University Hospital Essen, University of Duisburg-Essen, Essen, Germany.

To enhance the quality of real-world external comparative studies, it is essential to systematically identify, prespecify, and account for prognostic variables and effect measure modifiers (EMMs), especially between emulated target trial and real-world control arms. These factors can then be utilized to evaluate cohort comparability and perform covariate adjustments, such as in propensity score models. A systematic literature review (SLR)-based identification of prognostic factors, coupled with expert clinical review, offers a comprehensive approach to evaluating and ranking the level of evidence, while also assisting in selection of prognostic factors to assess imbalances between cohorts in single-arm trials and real-world data studies.

View Article and Find Full Text PDF

This phase II trial aims to determine the efficacy and safety of frontline acalabrutinib, lenalidomide and rituximab for patients with advanced stage follicular lymphoma (FL) and high tumor burden. The primary endpoint was best complete response (CR) rate; the secondary endpoints were overall response rate (ORR), duration of response measured as CR at 30 months (CR30), progression of disease at 24 months (POD24) rate, progression-free survival (PFS), overall survival and safety. Twenty-four patients with previously untreated FL were included in this phase 2 single arm study (NCT04404088).

View Article and Find Full Text PDF

Follicular lymphoma (FL) is the second most common lymphoma subtype diagnosed in Japan. Although FL is not curable, it generally has an indolent clinical course in the absence of histologic transformation to aggressive B-cell lymphoma. However, subsets of patients, including those with progression of disease within 24 months (POD24) and those refractory to rituximab and/or alkylators, have a worse prognosis when treated with conventional cytotoxic chemotherapies.

View Article and Find Full Text PDF